
Annual report 2025
added 02-13-2026
Outset Medical Retained Earnings 2011-2026 | OM
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Outset Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.17 B | -1.09 B | -962 M | -789 M | -626 M | - | -373 M | -288 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -288 M | -1.17 B | -757 M |
Quarterly Retained Earnings Outset Medical
| 2025-Q3 | 2024-Q4 | 2024-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.15 B | -1.09 B | - | - | - | - | -663 M | -626 M | -585 M | -554 M | -524 M | -494 M | -494 M | -494 M | -494 M | -373 M | -373 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -373 M | -1.15 B | -609 M |
Retained Earnings of other stocks in the Medical devices industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
-168 M | $ 2.12 | 0.47 % | $ 3.31 M | ||
|
AdaptHealth Corp.
AHCO
|
-633 M | $ 10.43 | 0.14 % | $ 1.41 B | ||
|
Allied Healthcare Products
AHPI
|
-15.7 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-533 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-600 M | - | -26.83 % | $ 2.62 M | ||
|
Butterfly Network
BFLY
|
-802 M | $ 4.07 | 4.09 % | $ 862 M | ||
|
Alphatec Holdings
ATEC
|
-1.42 B | $ 12.8 | 1.59 % | $ 1.92 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-185 M | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
-176 M | - | 1.37 % | $ 20.5 M | ||
|
Cognyte Software Ltd.
CGNT
|
-157 M | $ 8.62 | 2.86 % | $ 619 M | ||
|
Avinger
AVGR
|
-421 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
-317 M | - | -13.19 % | $ 166 K | ||
|
Boston Scientific Corporation
BSX
|
5.57 B | $ 71.13 | 1.96 % | $ 105 B | ||
|
CONMED Corporation
CNMD
|
589 M | $ 37.22 | -0.48 % | $ 1.16 B | ||
|
Conformis
CFMS
|
-581 M | - | - | $ 16.4 M | ||
|
Apollo Endosurgery
APEN
|
-337 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
-82.6 M | $ 3.96 | - | $ 148 M | ||
|
Cytosorbents Corporation
CTSO
|
-304 M | $ 0.69 | 6.14 % | $ 37.6 M | ||
|
Cutera
CUTR
|
-303 M | - | -10.19 % | $ 1.99 M | ||
|
Establishment Labs Holdings
ESTA
|
-496 M | $ 64.67 | 1.87 % | $ 1.92 B | ||
|
CryoLife, Inc.
CRY
|
20 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
-40.5 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
-191 M | $ 11.11 | 0.68 % | $ 300 M | ||
|
Axonics Modulation Technologies
AXNX
|
-374 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
-70.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-56.2 M | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-119 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-39.3 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-395 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
-33.6 M | $ 18.42 | - | $ 121 M | ||
|
Helius Medical Technologies
HSDT
|
-160 M | $ 2.21 | 0.83 % | $ 1.34 M | ||
|
GBS
GBS
|
-62.5 M | - | -0.57 % | $ 7.12 M | ||
|
Intersect ENT, Inc.
XENT
|
-303 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
969 M | $ 13.64 | 1.56 % | $ 882 M | ||
|
Abbott Laboratories
ABT
|
49.8 B | $ 110.89 | 0.85 % | $ 193 B | ||
|
IRIDEX Corporation
IRIX
|
-79 M | $ 1.33 | 0.01 % | $ 21.5 M | ||
|
Delcath Systems
DCTH
|
-529 M | $ 9.95 | 1.43 % | $ 356 M | ||
|
Bio-Rad Laboratories
BIO
|
7.42 B | $ 267.66 | 2.46 % | $ 7.55 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
940 M | $ 9.4 | 4.33 % | $ 724 M | ||
|
AxoGen
AXGN
|
-307 M | $ 32.75 | -0.27 % | $ 1.51 B | ||
|
LivaNova PLC
LIVN
|
-1.15 B | $ 62.35 | 1.5 % | $ 3.4 B | ||
|
Align Technology
ALGN
|
2.48 B | $ 176.2 | 3.98 % | $ 13.2 B | ||
|
Bruker Corporation
BRKR
|
2.41 B | $ 33.77 | 3.08 % | $ 5.03 K | ||
|
BioSig Technologies
BSGM
|
-255 M | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
-89.1 M | $ 3.85 | 4.9 % | $ 158 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-275 M | $ 17.2 | 0.53 % | $ 404 M | ||
|
Integer Holdings Corporation
ITGR
|
994 M | $ 86.22 | 2.5 % | $ 2.99 B | ||
|
Invacare Corporation
IVC
|
-78.4 M | - | - | $ 24.7 M |